The following handle holds various files of this Leiden University dissertation:
http://hdl.handle.net/1887/80330
Author: Boer, S.M. de
Title: Adjuvant treatment for endometrial cancer: efficacy, toxicity and quality of life
Issue Date: 2019-11-12
Adjuvant treatment for endometrial cancer Efficacy, toxicity and quality of life
Stephanie de Boer
ISBN: 978-94-6361-321-7
Cover design: Evelien Jagtman
Lay-out and print: Optima Grafische Communicatie, Rotterdam, The Netherlands Financial support for the publication of this thesis was kindly provided by Elekta and Chipsoft.
Adjuvant treatment for endometrial cancer Efficacy, toxicity and quality of life
Proefschrift
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden, op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties
te verdedigen op dinsdag 12 november 2019 klokke 15.00 uur
door
Stephanie Mariska de Boer geboren te Naarden op 28 november 1986
Prof. dr. H.W. Nijman, Universiteit Groningen Prof. dr. L.V. van de Poll-Franse, Universiteit Tilburg
The work presented in this thesis was financially supported by the Dutch Cancer Society (PORTEC-2:
CKVO 2001-04 and PORTEC 3: UL2006–4168/CKTO 2006–04)
Contents
Chapter 1 Introduction 7
Adapted from: Expert Review of Anticancer Therapy 2019 Jan;19(1):51-60
Chapter 2 Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results from the Randomized PORTEC-2 Trial
25
International Journal Radiation Oncology Biology and Physics 2015 Nov 15;93(4):797-809
Chapter 3 Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer
47 Annals of Oncology 2018 Feb 1;29(2):424-430
Chapter 4 Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial
67
The Lancet Oncology 2016 Aug; 17(8): 1114-1126
Chapter 5 Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
103
The Lancet Oncology 2018 Mar;19(3):295-309
Chapter 6 Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised, phase 3 trial
137
The Lancet Oncology, 2019 Sept; 20(9): 1273-1285
Chapter 7 General discussion and future perspectives 171
Appendices Nederlandse samenvatting 199
Author affiliations 207
PORTEC-3 participating groups and centres 213
List of publications and conference presentations 217
Curriculum vitae 221
Dankwoord 223
